Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update

Rhea-AI Summary

Rigel Pharmaceuticals will announce its third quarter 2021 financial results on November 2, 2021, after market close. Senior management will host a live conference call at 4:30 PM ET to discuss the results and provide a business update. Rigel specializes in developing small molecule drugs for hematologic disorders, cancer, and rare diseases. Its lead product, TAVALISSE, is the only oral SYK inhibitor for chronic immune thrombocytopenia. The company has multiple ongoing clinical trials for various conditions, including COVID-19 and autoimmune diseases.

Positive

• Rigel's TAVALISSE is the only oral SYK inhibitor approved for chronic immune thrombocytopenia.
• Robust pipeline with multiple Phase 3 clinical trials ongoing for critical health conditions.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2021 financial results after market close on Tuesday, November 2, 2021.  Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing, and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE^® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.

Fostamatinib is currently being studied in a Phase 3 clinical trial (NCT03764618) for the treatment of warm autoimmune hemolytic anemia (wAIHA)¹; a Phase 3 clinical trial (NCT04629703) for the treatment of hospitalized high-risk patients with COVID-19¹; an NIH/NHLBI-sponsored Phase 3 clinical trial (ACTIV-4 Host Tissue Trial, NCT04924660) for the treatment of COVID-19 in hospitalized patients, and a Phase 2 clinical trial (NCT04581954) for the treatment of COVID-19 being conducted by Imperial College London.

Rigel's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program, and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, Rigel has product candidates in development with partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

For further information, visit www.rigel.com or follow us on Twitter or LinkedIn.

Please see www.TAVALISSE.com for the full Prescribing Information.

¹The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

Investor Contact:
Jodi Sievers
Rigel Pharmaceuticals, Inc.
Phone: 650.624.1232
Email: ir@rigel.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2021-financial-results-and-business-update-301408145.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

When will Rigel Pharmaceuticals report its third quarter 2021 financial results?

Rigel Pharmaceuticals will report its third quarter 2021 financial results after market close on November 2, 2021.

What is the significance of TAVALISSE in Rigel's portfolio?

TAVALISSE is important as it is the only oral SYK inhibitor for treating chronic immune thrombocytopenia.

What updates can investors expect during the conference call on November 2, 2021?

Investors can expect updates on the third quarter financial results and the business outlook during the conference call.

What clinical trials is Rigel currently conducting?

Rigel is conducting Phase 3 trials for warm autoimmune hemolytic anemia and COVID-19, among other programs.